BR9809846A - Método para produzir um adenovìrus deficiente em replicação - Google Patents

Método para produzir um adenovìrus deficiente em replicação

Info

Publication number
BR9809846A
BR9809846A BR9809846-2A BR9809846A BR9809846A BR 9809846 A BR9809846 A BR 9809846A BR 9809846 A BR9809846 A BR 9809846A BR 9809846 A BR9809846 A BR 9809846A
Authority
BR
Brazil
Prior art keywords
replication
adenovirus
deficient adenoviruses
deficient
producing replication
Prior art date
Application number
BR9809846-2A
Other languages
English (en)
Inventor
Erick Falck-Pedersen
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Publication of BR9809846A publication Critical patent/BR9809846A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Electric Double-Layer Capacitors Or The Like (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<B>MéTODO PARA PRODUZIR UM ADENOVìRUS DEFICIENTE EM REPLICAçãO<D> Método para produzir um adenovírus de replicação deficitária, compreendendo um gene passageiro e uma deficiência em uma função genética essencial da região E1 de um adenovírus, compreendendo a produção do adenovírus em uma célula que fornece funções genéticas in trans das regiões E1 e E4 de um ou mais adenovírus não pertencendo ao mesmo sorogrupo que o adenovírus de replicação deficitária.
BR9809846-2A 1997-05-22 1998-05-20 Método para produzir um adenovìrus deficiente em replicação BR9809846A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/861,773 US5849561A (en) 1997-05-22 1997-05-22 Method for the production of non-group C adenoviral vectors
PCT/US1998/010367 WO1998053087A1 (en) 1997-05-22 1998-05-20 Method for the production of non-group c adenoviral vectors

Publications (1)

Publication Number Publication Date
BR9809846A true BR9809846A (pt) 2000-06-20

Family

ID=25336722

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809846-2A BR9809846A (pt) 1997-05-22 1998-05-20 Método para produzir um adenovìrus deficiente em replicação

Country Status (15)

Country Link
US (1) US5849561A (pt)
EP (1) EP0988389B1 (pt)
JP (1) JP2001527420A (pt)
AT (1) ATE325885T1 (pt)
AU (1) AU743923B2 (pt)
BR (1) BR9809846A (pt)
CA (1) CA2289611C (pt)
DE (1) DE69834489T2 (pt)
HU (1) HUP0003331A3 (pt)
IL (1) IL133011A0 (pt)
MX (1) MXPA99010787A (pt)
NZ (1) NZ500920A (pt)
PL (1) PL336941A1 (pt)
SK (1) SK156799A3 (pt)
WO (1) WO1998053087A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
AU764686B2 (en) * 1998-08-28 2003-08-28 Duke University Adenoviruses deleted in the IVa2, 100K, polymerase and/or preterminal protein sequences
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
WO2000060106A1 (en) * 1999-04-06 2000-10-12 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
CA2369491C (en) * 2000-02-02 2008-09-02 Yasufumi Kaneda Virus envelope vector for gene transfer
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
AU2002223556A1 (en) * 2000-09-20 2002-04-02 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de) * 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
AU2002332736A1 (en) * 2001-08-30 2003-03-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of New adenovirus type 7 vectors
EP1573035B1 (en) 2002-02-22 2015-09-02 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Brother of the regulator of imprinted sites (boris)
PL215165B1 (pl) * 2002-04-25 2013-10-31 Crucell Holland Bv Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego
JP4237449B2 (ja) 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
EP1539937A4 (en) * 2002-08-22 2006-07-26 Merck & Co Inc METHODS OF PROPAGATION OF ADENOVIRUS AND VIRUS SO OBTAINED
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US20040185555A1 (en) * 2003-03-17 2004-09-23 Emini Emilio A. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
EP1649028B1 (en) * 2003-07-25 2012-08-22 Genvec, Inc. Adenoviral vector-based vaccines
DE602004025726D1 (de) 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
EP2567967A3 (en) 2004-04-12 2013-08-21 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of using adenoviral vectors to induce an immune response
CA2589602A1 (en) * 2004-09-01 2006-04-13 Genvec, Inc. Adenoviral vectors able to transduce apcs, potential use in immune response generation
US9651543B2 (en) 2005-08-31 2017-05-16 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
CA2620495A1 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
US8450055B2 (en) * 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
CA2675022A1 (en) * 2007-01-09 2008-07-17 Genvec, Inc. Adenoviral vector-based malaria vaccines
EP2300053A1 (en) * 2008-06-04 2011-03-30 Cornell University Vaccines for prevention and treatment of addiction
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011116189A1 (en) 2010-03-17 2011-09-22 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
EP2654786B1 (en) 2010-12-20 2019-02-20 GenVec, Inc. Adenoviral vector-based dengue fever vaccine
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
US10004811B2 (en) 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
WO2013180967A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Herpes simplex virus vaccine
EP3189138A4 (en) 2014-09-07 2018-04-18 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
EP3565572A1 (en) 2017-01-07 2019-11-13 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
AU2018241252A1 (en) 2017-03-30 2019-10-03 The University Of Queensland Chimeric molecules and uses thereof
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
KR20200086670A (ko) 2017-10-13 2020-07-17 셀렉타 바이오사이언시즈, 인크. 항바이러스 전달 벡터 IgM 반응을 약화시키기 위한 방법 및 조성물
CN111818943A (zh) 2018-01-04 2020-10-23 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
JP2021515037A (ja) 2018-02-26 2021-06-17 アントルクス，インコーポレーテッド 寛容原性リポソーム及びその使用方法
US20200360453A1 (en) 2019-04-28 2020-11-19 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
CA3140019A1 (en) 2019-05-30 2020-12-03 Gritstone Bio, Inc. Modified adenoviruses
WO2021072129A2 (en) 2019-10-08 2021-04-15 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
CA2592997A1 (en) * 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP0638316B1 (en) * 1993-08-11 2003-05-28 Wyeth Recombinant adenovirus vaccines
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
EP0784690B1 (en) * 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
WO1996009399A2 (en) * 1994-09-23 1996-03-28 Somatix Therapy Corporation Chimeric adenovirus for gene delivery
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors

Also Published As

Publication number Publication date
WO1998053087A1 (en) 1998-11-26
EP0988389A1 (en) 2000-03-29
MXPA99010787A (es) 2005-12-12
DE69834489T2 (de) 2006-09-07
AU743923B2 (en) 2002-02-07
NZ500920A (en) 2001-04-27
JP2001527420A (ja) 2001-12-25
EP0988389B1 (en) 2006-05-10
HUP0003331A2 (hu) 2001-02-28
CA2289611C (en) 2009-11-03
CA2289611A1 (en) 1998-11-26
DE69834489D1 (de) 2006-06-14
SK156799A3 (en) 2000-05-16
HUP0003331A3 (en) 2003-01-28
ATE325885T1 (de) 2006-06-15
PL336941A1 (en) 2000-07-17
IL133011A0 (en) 2001-03-19
US5849561A (en) 1998-12-15
AU7584998A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
BR9809846A (pt) Método para produzir um adenovìrus deficiente em replicação
DE50203359D1 (de) Hopfenextrakte, verfahren zu ihrer herstellung und verwendung
BR9910251A (pt) Estimulação hematopoiética
BR9711745A (pt) Materiais e processos para a modificação do teor em lignina de plantas.
ATE295739T1 (de) ADENOVIRALE VEKTOREN BEINHALTEND EIN PROSTATA SPEZIFISCHES ANTIGEN (PSA) ßRESPONSE ELEMENTß
BRPI0408165A (pt) processos para melhorar a atividade das enzimas de degradação de lignocelulose
GEP20012559B (en) Complementary Adenoviral Vector Systems and Cells Lines
FI962799A (fi) Nukleiinihappoja sisältävä valmiste, sen valmistus ja käyttö
BR0214840A (pt) Genes
EP1180932A4 (en) ADENOVIRUS WITH REINFORCED AND CONDITIONALLY REPLICATED INFECTIVE POWER, AND APPLICATIONS THEREOF
BR9604825A (pt) Citostáticos modificados por carboidratos
AU6886996A (en) Building plaything primarily for creating rolling tracks
Varin et al. Novel flavonol 3-sulfotransferase. Purification, kinetic properties, and partial amino acid sequence.
AR027696A1 (es) Procedimiento para elaborar te de hoja soluble en agua fria
BR9712992A (pt) Máquina para processamento de folhas.
BR9811014A (pt) &#34;região concentrada reguladora de gene especìfica para semente precoce&#34;
BR9913997A (pt) Método e sistema para compartilhamento de carga de célula em um meio de seleção de célula controlada por estação móvel
ATE321843T1 (de) Zellen, kulturverfahren, und ihre verwendung in autologer transplantationstherapie
ITTV950058A0 (it) Struttura di dispositivo frenante, particolarmente per pattini con ruote in linea
WO2004035616A3 (de) Adenovirus mit umgekehrter reihenfolge der expression von genen und verwendung davon
BR0011322A (pt) Composições que afetam a morte programada de células e seu uso na modificação do desenvolvimento de plantas florestais
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
BR0213259A (pt) Método para produzir um composto bioativo apresentando uma bioatividade conhecida, e, células recombinantes
DE60033679D1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken
Coleman An examination of the relationship of structural pluralism, news role and source use with framing in the context of a community controversy.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O, 7O, 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1909 DE 07/08/2007.